DK2066669T3 - Adenosinderivater som A2A-receptoragonister - Google Patents

Adenosinderivater som A2A-receptoragonister

Info

Publication number
DK2066669T3
DK2066669T3 DK07803477.4T DK07803477T DK2066669T3 DK 2066669 T3 DK2066669 T3 DK 2066669T3 DK 07803477 T DK07803477 T DK 07803477T DK 2066669 T3 DK2066669 T3 DK 2066669T3
Authority
DK
Denmark
Prior art keywords
receptor agonists
adenosine derivatives
adenosine
derivatives
agonists
Prior art date
Application number
DK07803477.4T
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Roger John Taylor
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK2066669T3 publication Critical patent/DK2066669T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK07803477.4T 2006-09-14 2007-09-13 Adenosinderivater som A2A-receptoragonister DK2066669T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120706A EP1903044A1 (en) 2006-09-14 2006-09-14 Adenosine Derivatives as A2A Receptor Agonists
PCT/EP2007/059666 WO2008031875A1 (en) 2006-09-14 2007-09-13 Adenosine derivatives as a2a receptor agonists

Publications (1)

Publication Number Publication Date
DK2066669T3 true DK2066669T3 (da) 2011-01-10

Family

ID=37622170

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07803477.4T DK2066669T3 (da) 2006-09-14 2007-09-13 Adenosinderivater som A2A-receptoragonister

Country Status (31)

Country Link
US (1) US8188100B2 (da)
EP (2) EP1903044A1 (da)
JP (1) JP2010503639A (da)
KR (1) KR20090040386A (da)
CN (1) CN101511831B (da)
AR (1) AR062768A1 (da)
AT (1) ATE481404T1 (da)
AU (1) AU2007296227A1 (da)
BR (1) BRPI0716936A2 (da)
CA (1) CA2662104A1 (da)
CL (1) CL2007002658A1 (da)
CR (1) CR10621A (da)
CY (1) CY1110990T1 (da)
DE (1) DE602007009272D1 (da)
DK (1) DK2066669T3 (da)
ES (1) ES2353141T3 (da)
HK (1) HK1131392A1 (da)
HR (1) HRP20100694T1 (da)
IL (1) IL197153A0 (da)
MA (1) MA30722B1 (da)
MX (1) MX2009002811A (da)
NO (1) NO20091244L (da)
PE (1) PE20081151A1 (da)
PL (1) PL2066669T3 (da)
PT (1) PT2066669E (da)
RU (1) RU2009113668A (da)
SI (1) SI2066669T1 (da)
TN (1) TN2009000084A1 (da)
TW (1) TW200821324A (da)
WO (1) WO2008031875A1 (da)
ZA (1) ZA200901036B (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545787A (en) * 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
MX2008012929A (es) 2006-04-04 2008-12-17 Univ California Antagonistas de cinasa.
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
DK2013211T3 (da) 2006-04-21 2012-07-02 Novartis Ag Purinderivater til anvendelse som adenosin-A2A-receptoragonister
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
JP2009541436A (ja) * 2006-06-27 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） 治療用化合物
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP2084121A1 (en) * 2006-11-10 2009-08-05 Novartis AG Cyclopentene diol monoacetate derivatives
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
WO2009050199A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine al receptor ligands
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
SG187425A1 (en) 2008-01-04 2013-02-28 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN104995192A (zh) 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
MX2016012021A (es) 2014-03-19 2017-04-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
CN105012318B (zh) * 2014-04-17 2020-02-11 沈华浩 磺酰胺类化合物在气道慢性炎症性疾病中的应用
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161002A1 (en) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
HUE061989T2 (hu) * 2016-03-16 2023-09-28 Kura Oncology Inc Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2017281797A1 (en) 2016-06-24 2019-01-24 Infinity Pharmaceuticals, Inc. Combination therapies
JP2020514388A (ja) 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
KR102254660B1 (ko) 2017-09-28 2021-05-24 씨스톤 파마슈티컬즈 (상하이) 컴퍼니 리미티드 Ａ2ａ수용체 억제제로서의 축합 고리 유도체

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1528382A (en) * 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) * 1986-07-10 1989-10-10 Board Of Governors Of Wayne State University Process for the preparation of cyclopentanoids and novel intermediates produced thereby
IL84414A0 (en) 1986-11-14 1988-04-29 Ciba Geigy Ag N9-cyclopentyl-substituted adenine derivatives
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
JP2586897B2 (ja) 1987-03-09 1997-03-05 富士薬品工業株式会社 光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
AU654507B2 (en) 1990-09-25 1994-11-10 Rhone-Poulenc Rorer International (Holdings) Inc. Compounds having antihypertensive and anti-ischemic properties
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) * 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5691188A (en) * 1994-02-14 1997-11-25 American Cyanamid Company Transformed yeast cells expressing heterologous G-protein coupled receptor
ATE219767T1 (de) * 1996-01-02 2002-07-15 Aventis Pharm Prod Inc Verfahren zur herstellung von 2,4-dihydroxy- pyridin und 2,4-dihydroxy-3-nitropyridin
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
AU750322B2 (en) * 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
ATE246701T1 (de) 1998-06-23 2003-08-15 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
DE69932173T2 (de) 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
ATE275565T1 (de) * 1998-12-31 2004-09-15 Aventis Pharma Inc Verfahren zur herstellung von n6-substituierten deaza-adenosinderivaten
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
DE60203702T2 (de) 2001-01-16 2006-03-02 Can-Fite Biopharma Ltd. Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
GB2372741A (en) 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1258247A1 (en) * 2001-05-14 2002-11-20 Aventis Pharma Deutschland GmbH Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
NZ545787A (en) 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7414036B2 (en) * 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP1496911B1 (en) 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Use of a combination comprising a2a adenosine receptor agonists and anti-pathogenic agents for the treatment of inflammatory diseases
PL1699459T3 (pl) * 2003-12-29 2007-12-31 Can Fite Biopharma Ltd Sposób leczenia stwardnienia rozsianego
AU2005218997B2 (en) 2004-03-05 2012-05-10 Cbt Development Limited Adenosine receptor agonists
WO2005107463A1 (en) 2004-05-03 2005-11-17 University Of Virginia Patent Foundation Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
AR049384A1 (es) * 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US7825102B2 (en) * 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
EP1778239B1 (en) 2004-07-28 2013-08-21 Can-Fite Biopharma Ltd. Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
JP2008512457A (ja) * 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US20080051364A1 (en) * 2004-11-08 2008-02-28 Pninna Fishman Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
ME02012B (me) * 2005-02-04 2013-02-28 Millennium Pharm Inc INHIBITORI El AKTIVIRAJUĆIH ENZIMA
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007063538A1 (en) * 2005-11-30 2007-06-07 Can-Fite Biopharma Ltd. Use of a3 adenosine receptor agonist in osteoarthritis treatment
EP1983990B1 (en) * 2006-01-26 2011-03-23 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services A3 adenosine receptor allosteric modulators
SG169369A1 (en) * 2006-02-02 2011-03-30 Millennium Pharm Inc Inhibitors of e1 activating enzymes
WO2007092936A2 (en) * 2006-02-08 2007-08-16 University Of Virginia Patent Foundation Method to treat gastric lesions
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607951D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607954D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
DK2013211T3 (da) * 2006-04-21 2012-07-02 Novartis Ag Purinderivater til anvendelse som adenosin-A2A-receptoragonister
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP2084121A1 (en) * 2006-11-10 2009-08-05 Novartis AG Cyclopentene diol monoacetate derivatives
WO2008124150A1 (en) * 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) * 2007-04-23 2008-10-23 Adenosine Therapeutics, Llc Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
EP2170401A1 (en) * 2007-06-29 2010-04-07 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Dendrimer conjugates of agonists and antagonists of the gpcr superfamily
US20090181934A1 (en) * 2007-10-17 2009-07-16 Novartis Ag Organic Compounds
WO2009050199A1 (en) * 2007-10-17 2009-04-23 Novartis Ag Purine derivatives as adenosine al receptor ligands
US8183225B2 (en) * 2007-11-08 2012-05-22 New York University Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
JP2011509305A (ja) * 2008-01-09 2011-03-24 ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療

Also Published As

Publication number Publication date
NO20091244L (no) 2009-04-07
US8188100B2 (en) 2012-05-29
CN101511831B (zh) 2012-04-25
HK1131392A1 (en) 2010-01-22
AU2007296227A1 (en) 2008-03-20
SI2066669T1 (sl) 2011-01-31
ES2353141T3 (es) 2011-02-25
CL2007002658A1 (es) 2008-08-08
RU2009113668A (ru) 2010-10-20
BRPI0716936A2 (pt) 2013-09-17
EP2066669A1 (en) 2009-06-10
MA30722B1 (fr) 2009-09-01
CN101511831A (zh) 2009-08-19
KR20090040386A (ko) 2009-04-23
CY1110990T1 (el) 2015-06-11
ZA200901036B (en) 2010-01-27
EP1903044A1 (en) 2008-03-26
JP2010503639A (ja) 2010-02-04
DE602007009272D1 (de) 2010-10-28
TN2009000084A1 (en) 2010-08-19
CR10621A (es) 2009-03-27
PL2066669T3 (pl) 2011-03-31
CA2662104A1 (en) 2008-03-20
WO2008031875A1 (en) 2008-03-20
PT2066669E (pt) 2010-12-17
TW200821324A (en) 2008-05-16
ATE481404T1 (de) 2010-10-15
EP2066669B1 (en) 2010-09-15
US20090325967A1 (en) 2009-12-31
MX2009002811A (es) 2009-03-31
PE20081151A1 (es) 2008-10-06
AR062768A1 (es) 2008-12-03
IL197153A0 (en) 2009-11-18
HRP20100694T1 (hr) 2011-01-31

Similar Documents

Publication Publication Date Title
DK2066669T3 (da) Adenosinderivater som A2A-receptoragonister
DK2013211T3 (da) Purinderivater til anvendelse som adenosin-A2A-receptoragonister
DK2018388T3 (da) Bisadenosinforbindelser som adenosin A2A-receptoragonister
DK1841768T3 (da) Purinderivater virkende som A2A-receptoragonister
DK2206710T3 (da) Indolderivater som s1p1-receptor agonister
DK1863474T3 (da) Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
BRPI0817503A2 (pt) Derivados de purina substituídos por pirimidina
DK1912991T3 (da) Xanthinderivater som selektive HM74A-Agonister
DK2125792T3 (da) Purinderivater som immunomodulatorer
DK2225231T3 (da) Aminotriazolderivater som alx-agonister
DK1856110T3 (da) Oxyindol derivater som 5HT4-receptor agonister
DK1989196T3 (da) Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
DK2078001T3 (da) Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
ZA200810671B (en) Purine derivatives as A2A agonists
ATE486874T1 (de) Purinonderivate als hm74a-agonisten
DK2007396T3 (da) Enfumafungin-derivat som antimykotika
DE502007004416D1 (de) Avermectinderivate
DK2276756T3 (da) Hydroxymethylpyrrolidiner som beta 3-adrenerge receptoragonister